Erectile dysfunction

New England Journal of Medicine

Volumn 342, Issue 24, 2000, Pages 1802-1813

  Lue, Tom F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; APOMORPHINE; CYCLIC GMP; DIHYDROERGOTOXINE MESILATE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; NITRIC OXIDE; PAPAVERINE; PHENTOLAMINE; PLACEBO; PROSTAGLANDIN E1; PROSTAVASIN; SILDENAFIL; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TRAZODONE; TRIMIX; VASOACTIVE INTESTINAL POLYPEPTIDE; YOHIMBINE;

AGING; ANDROGEN THERAPY; CLINICAL TRIAL; CORPUS CAVERNOSUM; DEVICE; DRUG MIXTURE; ERECTILE DYSFUNCTION; HUMAN; HYPOGONADISM; MALE; PATHOPHYSIOLOGY; PENIS ERECTION; PENIS PROSTHESIS; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SEXUAL INTERCOURSE; SIDE EFFECT;

ADRENERGIC ANTAGONISTS; AGING; ANDROGENS; DRUG COMBINATIONS; HUMANS; IMPOTENCE; MALE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0034660235     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200006153422407     Document Type: Review

References (73)

1. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA 1993;270:83-90.
2. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995;22:699-709.
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
4. Fournier GR Jr, Juenemann KP, Lue TF, Tanagho EA. Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration. J Urol 1987;137:163-7.
5. Banya Y, Ushiki T, Takagane H, et al. Two circulatory routes within the human corpus cavernosum penis: a scanning electron microscopic study of corrosion casts. J Urol 1989;142:879-83.
6. Lue TF, Tanagho EA. Hemodynamics of erection. In: Tanagho EA, Lue TF, McClure RD, eds. Contemporary management of impotence and infertility. Baltimore: Williams & Wilkins, 1988:28-38.
7. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
8. Saenz de Tejada I, Kim N, Lagan I, Krane RJ, Goldstein I. Regulation of adrenergic activity in penile corpus cavernosum. J Urol 1989;142:1117-21.
9. Italiano G, Calabrò A, Spini S, Ragazzi E, Pagano F. Functional response of cavernosal tissue to distension. Urol Res 1998;26:39-44.
10. Gondré M, Christ GJ. Endothelin-1-induced alterations in phenylephrine-induced contractile responses are largely additive in physiologically diverse rabbit vasculature. J Pharmacol Exp Ther 1998;286:635-42.
11. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-30.
12. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170:843-50.
13. Christ GJ, Brink PR, Melman A, Spray DC. The role of gap junctions and ion channels in the modulation of electrical and chemical signals in human corpus cavernosum smooth muscle. Int J Impot Res 1993;5:77-96.
14. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998;60:458-65.
15. Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 1998;52:848-52.
16. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137-41.
17. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983;12:59-66.
18. Levine FJ, Greenfield AJ, Goldstein I. Arteriographically determined occlusive disease within the hypogastric-cavernous bed in impotent patients following blunt perineal and pelvic trauma. J Urol 1990;144:1147-53.
19. Rosen MP, Greenfield AJ, Walker TG, et al. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol 1991;145:759-63.
20. Hsieh JT, Lue TF, Muller SC, et al. The influence of blood flow and blood pressure on penile erection. Int J Impot Res 1989;1:35-42.
21. Rajfer J, Rosciszewski A, Mehringer M. Prevalence of corporeal venous leakage in impotent men. J Urol 1988;140:69-71.
22. Christ GJ, Maayani S, Valcic M, Melman A. Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol 1990;101:375-81.
23. Juenemann K-P, Lue TF, Luo JA, Benowitz NL, Abozeid M, Tanagho EA. The effect of cigarette smoking on penile erection. J Urol 1987;138: 438-41.
24. Miller NS, Gold MS. The human sexual response and alcohol and drugs. J Subst Abuse Treat 1988;5:171-7.
25. Wolfe MM. Impotence on cimetidine treatment. N Engl J Med 1979; 300:94.
26. Masters WH, Johnson VE. Sex after sixty-five. Reflections 1977;12:31-43.
27. Rowland DL, Greenleaf W, Mas M, Myers L, Davidson JM. Penile and finger sensory thresholds in young, aging, and diabetic males. Arch Sex Behav 1989;18:1-12.
28. Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988;36:511-9.
29. Nogues MA, Starkstein S, Davalos M, Berthier M, Leiguarda R, Garcia H. Cardiovascular reflexes and pudendal evoked responses in chronic haemodialysis patients. Funct Neurol 1991;6:359-65.
30. Lue T. Impotence: a patient's goal-directed approach to treatment. World J Urol 1990;8:67-74.
31. Schiavi RC, White D, Mandeli J, Levine AC. Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav 1997;26:231-41.
32. Morales A, Johnston B, Heaton JW, Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994;152:1115-8.
33. Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996;155:1604-8.
34. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-51.
35. Hong EK, Lepor H, McCullough AR. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Im J Impot Res 1999;11:Suppl 1: S15-S22.
36. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404. [Erratum, N Engl J Med 1998;339:59.]
37. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69-73.
38. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998;15:821-5.
39. Muller JE, Mittleman A, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. JAMA 1996;275:1405-9.
40. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999;99:168-77. [Erratum, Circulation 1999;100:2389.]
41. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159: 433-6.
42. Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988;109:162-3.
43. Zorgniotti AW. Experience with buccal phentolamine mesylate for impotence. Int J Impot Res 1994;6:37-41.
44. Goldstein I, Vasomax Study Group. Efficacy and safety of oral phentolamine (Vasomax) for the treatment of minimal erectile dysfunction. J Urol 1998;159:Suppl:240. abstract.
45. Heaton JP, Morales A, Adams MA, Johnston B, el-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology 1995;45:200-6.
46. Padma-Nathan H, Fromm-Freeck S, Ruff DD, McMurray JG, Rosen RC, Apomorphine SL Study Group. Efficacy and safety of apomorphine SL vs placebo for male erectile dysfunction (MED). J Urol 1998;159: Suppl:241. abstract.
47. Lance R, Albo M, Costabile RA, Steers WD. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology 1995;46:117-20.
48. Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology 1994;44:732-6.
49. Meinhardt W, Schmitz PI, Kropman RF, de la Fuente RB, Lycklama à Nijeholt AA, Zwartendijk J. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res 1997;9:163-5.
50. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997;336:1-7.
51. Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br J Urol 1998;81:889-94.
52. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil - a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997;9:187-92.
53. Werthman P, Rajfer J. MUSE therapy: preliminary clinical observations. Urology 1997;50:809-11.
54. Lewis RW. Combined use of transurethral alprostadil and an adjustable penile constriction band in men with erectile dysfunction: results from a multicenter trial. J Urol 1998;159:Suppl:237. abstract.
55. Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997;79:958-63.
56. Stief CG, Wetterauer U. Erectile responses to intracavernous papaverine and phentolamine: comparison of single and combined delivery. J Urol 1988;140:1415-6.
57. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am 1995;22:833-45.
58. Juenemann K, Alken P. Pharmacotherapy of erectile dysfunction: a review. Int J Impot Res 1989;1:71-93.
59. Stackl W, Hasun R, Marberger M. Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988;140:66-8.
60. Lee LM, Stevenson RW, Szasz G. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J Urol 1989;141:549-50.
61. Linet OI, Neff LL. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Invest 1994;72:139-49.
62. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996;155:802-15.
63. Chew KK, Stuckey BG, Earle CM, Dhaliwal SS, Keogh EJ. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res 1997;9:225-9.
64. Canale D, Giorgi PM, Lencioni R, Morelli G, Gasperi M, Macchia E. Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction. Int J Androl 1996;19:28-32.
65. Kiely EA, Bloom SR, Williams G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br J Urol 1989;64:191-4.
66. Dinsmore WW, Alderdice DK. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998;81:437-40.
67. Zaher TF. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy. Int Urol Nephrol 1998;30:193-6.
68. Mirone V, Imbimbo C, Fabrizio F, Longo N, Palmieri A. Ketanserin plus prostaglandin E1 (PGE-1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE-1 alone. Br J Urol 1996;77:736-9.
69. Meinhardt W, de la Fuente RB, Lycklama à Nijeholt AA, Vermeij P, Zwartendijk J. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Int J Impot Res 1996;8:5-7.
70. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991;146: 1564-5.
71. Weiss JN, Badlani GH, Ravalli R, Brettschneider N. Reasons for high drop-out rate with self injection therapy for impotence. Int J Impot Res 1994;6:171-4.
72. Gupta R, Kirschen J, Barrow RC II, Eid JF. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997; 157:1681-6.
73. Gomaa A, Shalaby M, Osman M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. BMJ 1996;312:1512-5.